Furthermore, to maintain systemic cholesterol homeostasis and reduce ATP depletion of de novo cholesterol biosynthesis, some cancer cells alter mevalonate pathway enzyme expression and deregulate cholesterol influx/efflux genes, such as VLDLR, LDLR, SR-B1 and ABCA1, which in turn may lead to cancer cell resistance to statins (Riscal et al., 2019). Here, LDLR is linked to cancer.